Free Trial
NASDAQ:GALT

Galectin Therapeutics (GALT) Stock Price, News & Analysis

Galectin Therapeutics logo
$4.25 +0.27 (+6.78%)
Closing price 04:00 PM Eastern
Extended Trading
$4.14 -0.11 (-2.47%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Galectin Therapeutics Stock (NASDAQ:GALT)

Key Stats

Today's Range
$3.97
$4.35
50-Day Range
$2.09
$4.25
52-Week Range
$0.73
$4.41
Volume
275,225 shs
Average Volume
247,439 shs
Market Capitalization
$272.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Buy

Company Overview

Galectin Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

GALT MarketRank™: 

Galectin Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 596th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Galectin Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Galectin Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Galectin Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Galectin Therapeutics are expected to decrease in the coming year, from ($0.73) to ($0.92) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Galectin Therapeutics is -6.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Galectin Therapeutics is -6.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Galectin Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    17.76% of the float of Galectin Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Galectin Therapeutics has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Galectin Therapeutics has recently increased by 0.13%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Galectin Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Galectin Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.76% of the float of Galectin Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Galectin Therapeutics has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Galectin Therapeutics has recently increased by 0.13%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Galectin Therapeutics has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Galectin Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    8 people have searched for GALT on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added Galectin Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Galectin Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,920.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    50.10% of the stock of Galectin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 11.68% of the stock of Galectin Therapeutics is held by institutions.

  • Read more about Galectin Therapeutics' insider trading history.
Receive GALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GALT Stock News Headlines

Q3 EPS Estimate for Galectin Therapeutics Lifted by Analyst
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.tc pixel
Galectin Therapeutics Inc. (GALT) - Yahoo Finance
Galectin Therapeutics Inc.
See More Headlines

GALT Stock Analysis - Frequently Asked Questions

Galectin Therapeutics' stock was trading at $1.29 at the beginning of 2025. Since then, GALT shares have increased by 229.5% and is now trading at $4.25.

Galectin Therapeutics Inc. (NASDAQ:GALT) released its earnings results on Thursday, August, 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.04.

Galectin Therapeutics' top institutional shareholders include Jane Street Group LLC (1.18%), Geode Capital Management LLC (1.05%), Wealthspire Advisors LLC (0.76%) and Affinity Asset Advisors LLC. Insiders that own company stock include James C Czirr, Joel Lewis, Kary Eldred, Richard A Jr Zordani, Kevin D Freeman, Khurram Jamil, Harold H Shlevin and Jack W Callicutt.
View institutional ownership trends
.

Shares of GALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Galectin Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

Last Earnings
8/14/2025
Today
8/28/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GALT
CIK
1133416
Employees
9
Year Founded
2001

Price Target and Rating

High Price Target
$6.00
Low Price Target
$6.00
Potential Upside/Downside
+41.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.64)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$47.05 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-225.32%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.43
Quick Ratio
1.43

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.86) per share
Price / Book
-2.28

Miscellaneous

Outstanding Shares
64,060,000
Free Float
31,966,000
Market Cap
$272.26 million
Optionable
Optionable
Beta
0.82

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:GALT) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners